AstraZeneca tozorakimab cuts COPD flare-ups in trials

That matters because eosinophils are often used to help decide which COPD patients are most likely to respond to biologic treatment. If confirmed and approved, tozorakimab could broaden the market beyond the narrower, biomarker-defined groups that have typically shaped COPD biologics, giving physicians a new option for patients still having dangerous exacerbations despite existing therapy.

The company said reductions in flare-ups topped 40% in patients with eosinophil counts of at least 300, while patients below and above 150 also saw declines of more than 20% and 30%, respectively. AstraZeneca described tozorakimab as a first-in-class monoclonal antibody that blocks IL-33, a key inflammatory pathway tied to COPD and mucus dysfunction.

For investors, the read-through is twofold: the data reinforce AstraZeneca’s push to build a larger respiratory franchise beyond its established inhaled and biologic medicines, and they add another potential growth driver as the company leans on late-stage innovation to offset patent risk elsewhere in the portfolio. AstraZeneca shares were little changed in recent trading, while the stock had been holding above both its 50-day and 200-day moving averages in early September.

The next catalyst is regulatory and follow-up clinical work, including whether AstraZeneca can turn the phase III signal into an approved therapy with a commercial profile large enough to matter in a COPD market where unmet need remains high and exacerbations drive most of the cost burden.